Agios Pharmaceuticals (AGIO)

$27.93 -0.23 (-0.82%)
Market Cap 1.60B
Revenue (ttm) 36.50M
Net Income (ttm) 673.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1,845.84%
Debt to Equity Ratio 0.00
Volume 638,190
Avg Vol 1,875,394
Day's Range N/A - N/A
Shares Out 58.31M
Stochastic %K 50%
Beta 0.89
Analysts Strong Sell
Price Target $36.75

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatr...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Address:
88 Sidney Street, Cambridge, United States
MitchellMarkets1
MitchellMarkets1 Feb. 3 at 8:20 PM
$AGIO thin liquidity biotech under the radar watching for breakout attempt
0 · Reply
stu4
stu4 Feb. 3 at 12:44 PM
$AGIO 90 days running of the continuous failures of senior execs here ..Nov 19, 2025….was the hint, they are clueless
0 · Reply
stu4
stu4 Feb. 3 at 12:10 PM
$AGIO another RED DAY ..2500 and counting Loser Chairwoman , loser CEO ….employees that are 3rd rate in their field …all spells LOSERS Lower value since 2018, Fouse’s arrival Lower value since 2022, Goff arrived Ya can’t make this shit up…DOW hitting records. Already and this pos , has been auctioned off, grabbed old royalties Just so mgmt has jobs !!! Value creators they are not !!! Never will be , after 8 years of the Fouse .
0 · Reply
stu4
stu4 Feb. 3 at 1:32 AM
$AGIO you deserve this stock , lol ..you can’t even count I was here Thursday ..that’s 4 days ..or 2 days of the market Goff cab attract the dumbest
0 · Reply
Dkll303
Dkll303 Feb. 3 at 1:07 AM
$AGIO Shows how much interest there is in your pos stock and senior execs !!! You answered your own calling !! Loser call
0 · Reply
putsbydayhumanbynight
putsbydayhumanbynight Feb. 2 at 11:54 PM
$AGIO went thru 5 days without seeing the two bashers. Must be a miracle.
0 · Reply
stu4
stu4 Jan. 28 at 2:46 PM
$AGIO called it yesterday, the pump run for the losers .today no volume , Morgan cashed the check !!! SUCKERS
0 · Reply
Dkll303
Dkll303 Jan. 27 at 9:32 PM
$AGIO Don’t hold you breath …for you shall die : WATCHING , lol , senior execs DO NOT have the ability to render shareholders a big knock out company , for they are losers themselves !!! Mark the post !!!!
0 · Reply
Dkll303
Dkll303 Jan. 27 at 9:30 PM
$AGIO you forgot to mention that the losers at AGIO, have nothing in the hopper but innuendos and hype
0 · Reply
Quantumup
Quantumup Jan. 27 at 8:48 PM
Truist⬆️the PT on $NUVB to $13 from $11 and reiterated at Buy. $BMY $RHHBY PFE NVS Servier $RIGL $AGIO Truist said in its note: Following the Ibtrozi 4Q25 pre-report and our 1x1 with management, we believe the Ibtrozi franchise has shown robust opportunity out of the gate, with stronger-than-anticipated uptake, despite seasonal headwinds, positioning Ibtrozi as the ROS1 agent of choice versus competitors. As we await clarity on registrational timelines for safu' (noting readouts as early as this year), we see potential for upside in the mIDH1 glioma opportunity, bringing our PT to $13 (from $11).
0 · Reply
Latest News on AGIO
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Jan 26, 2026, 7:00 AM EST - 8 days ago

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:36 PM EST - 20 days ago

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Jan 12, 2026, 7:00 AM EST - 22 days ago

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Dec 24, 2025, 4:56 PM EST - 5 weeks ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Dec 24, 2025, 12:48 PM EST - 5 weeks ago

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 9:56 AM EST - 5 weeks ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 24, 2025, 8:22 AM EST - 5 weeks ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 23, 2025, 7:45 PM EST - 5 weeks ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Dec 8, 2025, 7:00 AM EST - 2 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Nov 19, 2025, 2:33 PM EST - 2 months ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Why Is Agios Pharmaceuticals Stock Sinking Today?

Nov 19, 2025, 12:30 PM EST - 2 months ago

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 8:24 AM EST - 2 months ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 19, 2025, 7:00 AM EST - 2 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Nov 4, 2025, 1:47 AM EST - 3 months ago

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 3 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 2:06 PM EDT - 3 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 30, 2025, 6:30 AM EDT - 3 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:15 AM EDT - 3 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 3 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Sep 18, 2025, 5:49 AM EDT - 4 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Sep 15, 2025, 12:20 PM EDT - 5 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Sep 8, 2025, 10:32 AM EDT - 5 months ago

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Sep 4, 2025, 12:46 PM EDT - 5 months ago

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Sep 4, 2025, 10:49 AM EDT - 5 months ago

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Sep 4, 2025, 7:00 AM EDT - 5 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Aug 4, 2025, 4:01 PM EDT - 6 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:02 PM EDT - 6 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 6:30 AM EDT - 6 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 14, 2025, 7:00 AM EDT - 7 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jul 8, 2025, 7:00 AM EDT - 7 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Jun 9, 2025, 8:40 AM EDT - 8 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 28, 2025, 7:00 AM EDT - 8 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 14, 2025, 10:00 AM EDT - 9 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 9, 2025, 7:00 AM EDT - 9 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 2, 2025, 7:00 AM EDT - 9 months ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:06 PM EDT - 9 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 6:30 AM EDT - 9 months ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Apr 17, 2025, 7:00 AM EDT - 10 months ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 5, 2025, 5:52 PM EST - 11 months ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Agios to Present at Upcoming Investor Conferences

Mar 4, 2025, 7:00 AM EST - 1 year ago

Agios to Present at Upcoming Investor Conferences

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 1:32 PM EST - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:31 AM EST - 1 year ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Feb 13, 2025, 6:30 AM EST - 1 year ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Feb 6, 2025, 7:00 AM EST - 1 year ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Jan 8, 2025, 8:00 AM EST - 1 year ago

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BIIB

MitchellMarkets1
MitchellMarkets1 Feb. 3 at 8:20 PM
$AGIO thin liquidity biotech under the radar watching for breakout attempt
0 · Reply
stu4
stu4 Feb. 3 at 12:44 PM
$AGIO 90 days running of the continuous failures of senior execs here ..Nov 19, 2025….was the hint, they are clueless
0 · Reply
stu4
stu4 Feb. 3 at 12:10 PM
$AGIO another RED DAY ..2500 and counting Loser Chairwoman , loser CEO ….employees that are 3rd rate in their field …all spells LOSERS Lower value since 2018, Fouse’s arrival Lower value since 2022, Goff arrived Ya can’t make this shit up…DOW hitting records. Already and this pos , has been auctioned off, grabbed old royalties Just so mgmt has jobs !!! Value creators they are not !!! Never will be , after 8 years of the Fouse .
0 · Reply
stu4
stu4 Feb. 3 at 1:32 AM
$AGIO you deserve this stock , lol ..you can’t even count I was here Thursday ..that’s 4 days ..or 2 days of the market Goff cab attract the dumbest
0 · Reply
Dkll303
Dkll303 Feb. 3 at 1:07 AM
$AGIO Shows how much interest there is in your pos stock and senior execs !!! You answered your own calling !! Loser call
0 · Reply
putsbydayhumanbynight
putsbydayhumanbynight Feb. 2 at 11:54 PM
$AGIO went thru 5 days without seeing the two bashers. Must be a miracle.
0 · Reply
stu4
stu4 Jan. 28 at 2:46 PM
$AGIO called it yesterday, the pump run for the losers .today no volume , Morgan cashed the check !!! SUCKERS
0 · Reply
Dkll303
Dkll303 Jan. 27 at 9:32 PM
$AGIO Don’t hold you breath …for you shall die : WATCHING , lol , senior execs DO NOT have the ability to render shareholders a big knock out company , for they are losers themselves !!! Mark the post !!!!
0 · Reply
Dkll303
Dkll303 Jan. 27 at 9:30 PM
$AGIO you forgot to mention that the losers at AGIO, have nothing in the hopper but innuendos and hype
0 · Reply
Quantumup
Quantumup Jan. 27 at 8:48 PM
Truist⬆️the PT on $NUVB to $13 from $11 and reiterated at Buy. $BMY $RHHBY PFE NVS Servier $RIGL $AGIO Truist said in its note: Following the Ibtrozi 4Q25 pre-report and our 1x1 with management, we believe the Ibtrozi franchise has shown robust opportunity out of the gate, with stronger-than-anticipated uptake, despite seasonal headwinds, positioning Ibtrozi as the ROS1 agent of choice versus competitors. As we await clarity on registrational timelines for safu' (noting readouts as early as this year), we see potential for upside in the mIDH1 glioma opportunity, bringing our PT to $13 (from $11).
0 · Reply
freddie04
freddie04 Jan. 27 at 6:51 PM
$AGIO thus RED, lol ..Morgan left did their job, cashed the check and stu4 called it ( market was down on the open, that had nothing to do with RED , hahaha it was green AM ) Once again : 65% NEGATIVE RETURN in 7 years , since FOUSE HAS BEEN ON THE PROPERTY 0% in 3.5 years while GOFF has been on the property And the idiot @StockConsultant , lol , sells you a GAP Did they sell you the GAP DOWN November 19 2025 , from 45 to $30 hahaha, never recovered because these execs aren’t credible or competent.
0 · Reply
stu4
stu4 Jan. 27 at 6:42 PM
$AGIO All the execs sold today , a round of applause for Morgan Stanley…moving the stock up for the LOSERS in MANAGEMENT!!! Goff, Milanova , Jones , Sarah G You all know the failures that keep sucking down the treasury and NO RESULTS
0 · Reply
stu4
stu4 Jan. 27 at 5:17 PM
$AGIO 340,000 shares by 12 PM, is degenerate senior execs selling on the window before earnings They know they suck that bad
0 · Reply
stu4
stu4 Jan. 27 at 5:14 PM
$AGIO Ya get all the losers options sold yet, Morgan Stanley ??? Aiding the handicapped senior execs that can’t create value for their own options , hahahah Goff’s “ hire on options “ are $29.38 , 3.5 years later, this bufffoon hasn’t even done himself good , lol , LOSER
0 · Reply
stu4
stu4 Jan. 27 at 3:48 PM
$AGIO Definite insiders selling ..thanks Morgan Stanley, lol
0 · Reply
Mindmld
Mindmld Jan. 27 at 3:47 PM
$AGIO monster gap to fill after 30, one of the more dramatic squeeze potentials around. Some bullshit is going to hit a wall.
0 · Reply
stu4
stu4 Jan. 27 at 2:00 PM
$AGIO I would rather watch porn !!! Guaranteed to give more satisfaction and adrenaline !!! Watch CRWV , ya know , real value oriented senior execs, not milking the big tit !
0 · Reply
Dkll303
Dkll303 Jan. 27 at 1:55 PM
$AGIO Morgan Stanley just rang the bell…window is open for the mgmt to sell…sell ..sell…
1 · Reply
Dkll303
Dkll303 Jan. 27 at 1:40 PM
$AGIO Never happen. like Trump saying “ I never met the woman “ “ I don’t know Epstein “ ( he is in the files 15000, times ) No talent here for such a pathetic suggestion @StockConsultant
0 · Reply
StockConsultant
StockConsultant Jan. 27 at 1:36 PM
$AGIO Agios Pharmaceuticals stock, watch for an upside gap breakout
0 · Reply
Dkll303
Dkll303 Jan. 27 at 12:20 PM
$AGIO Time for a little run…misfit senior execs , believed Sept 2025, the drug would have been approved and. Higher price for their 1st qtr ,DUMP, of options ..well it is not and their options are out the money …so Morgan Stanley gets the call, being their brokerage house of record for the DUMP and Feb 12 is earnings …so the window is now open, for the misfits to sell as they do every qtr . They know they suck, they fumble, unlike Drake Maye, they are all 60 year old fcuks wanting the big tit of money to continue for them !!! Drake earned his incentives , theses ASS HOLES here rely on Morgan Stanley, each and every qtr , to RUN the STOCK
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 22 at 10:37 PM
$AGIO RSI: 59.47, MACD: -0.3144 Vol: 0.98, MA20: 27.65, MA50: 29.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply